908 Devices Increases Focus on Biotherapeutics with Expansion of Scientific Advisory Board
07 5월 2021 - 8:00PM
Business Wire
Company Appoints Six New Members to its
Scientific Advisory Board
908 Devices (NASDAQ: MASS), a pioneer of purpose-built handheld
and desktop mass spec devices for chemical and biomolecular
analysis, today announced the forthcoming appointment of six new
individuals to its Scientific Advisory Board (SAB), including
Professor Michael Betenbaugh, Dr. Tim Charlebois, Dr. Elena
Chernokalskaya, Dr. John Erickson, Professor Krishnedndu Roy and
Dr. Gene Schaefer. The new SAB members join the board’s co-chairs
Christopher D. Brown, CTO of 908 Devices, and J. Michael Ramsey,
Scientific Founder of 908 Devices and Professor at UNC Chapel
Hill.
“We are honored to be welcoming Michael, Tim, Elena, John,
Krishnedndu and Eugene to our Scientific Advisory Board,” said Dr.
Christopher D. Brown, CTO and co-founder of 908 Devices. “Their
expertise and deep knowledge of the space of bioprocess
development/optimization, and cell and gene therapy
processes/production will be invaluable in helping us achieve our
long-term goals for expansion of the Rebel and ZipChip
ecosystems.”
908 Devices intends to create a bioanalytics platform leveraging
its versatile technologies including the REBEL to support users
from biotherapeutic development through production. The expansion
of its Scientific Advisory Board is a key step in supporting this
goal. This newly formed bioprocessing and biotherapeutics panel of
world-renowned industry leaders spans academic leaders at the
forefront of CGT and bioprocess optimization, to seasoned industry
leaders in process development, scale up and production. The depth
and breadth of this panel will be instrumental in providing
feedback and guidance on the company’s near- and long-term
technology roadmap.
The roster of new Scientific Advisory Board members
includes:
- Michael Betenbaugh, Ph.D.: Michael is a Professor of
Chemical and Biomolecular engineering at Johns Hopkins University
and the lead PI of the nationally recognized Advanced Mammalian
Biomanufacturing Innovation Center (AMBIC). He is one of the
pioneers of eukaryotic metabolic engineering, and a world-renowned
expert in CHO bioprocess optimization, metabolism and
glycoengineering.
- Tim Charlebois, Ph.D: Tim will be joining the SAB in
June following his retirement after a 30-year career in
biopharmaceutical development at Pfizer, most recently, and legacy
companies Wyeth and Genetics Institute. As VP of Technology &
Innovation at Pfizer, he has been responsible for technology
strategy and platform development across bioprocess, analytical,
formulation and delivery for the biologics and large molecule
portfolio, as well as in-licensing and out-licensing due diligence
and intellectual property support.
- Elena Chernokalskaya, Ph.D.: Elena brings over 20 years
of industrial R&D leadership in biopharma, CRO and device
manufacturing companies. In her most recent role as an Executive,
Upstream Bioprocess R&D at GE Life Sciences, Elena was
responsible for the development of Xcellerex bioreactors and
mixers, hollow fiber filters and HyClone cell culture media. She
also led the development and launch of the first GE single-use
platform film, Fortem.
- John Erickson, Ph.D.: John is the Acting Chief
Technology Officer at The National Institute for Innovation in
Manufacturing Biopharmaceuticals (NIIMBL), and was previously VP of
Biopharmaceutical and Sterile Manufacturing Science &
Technology at GSK. John brings over 30 years of experience in
biopharmaceutical process development, clinical trial supply and
commercial manufacturing.
- Krishnedndu Roy, Ph.D.: Krish is a Professor and Robert
A. Milton Endowed Chair in Biomedical Engineering at Georgia Tech,
and is a world-leader in the area of cell manufacturing and
biotherapeutics delivery. He serves as the Director of the NSF
Engineering Research Center for Cell Manufacturing Technologies and
The Marcus Center for Cell-Therapy Characterization and
Manufacturing, as well as the Director of the Center for
ImmunoEngineering.
- Eugene Schaefer, Sc.D.: Gene has held a wide variety of
roles in the biopharmaceutical industry over his distinguished
career in the last 36 years. Most recently he was Senior Director,
API Large Molecule BioTherapeutics Development at Janssen
(J&J). Prior to joining Janssen in 2008, Dr. Schaefer held
senior positions in process development and manufacturing of
therapeutic proteins and gene therapy vectors at Bristol-Myers
Squibb, Schering Plough, and Genzyme.
To learn more, visit www.908Devices.com.
About 908 Devices
908 Devices (NASDAQ:MASS) is democratizing laboratory mass
spectrometry with its simple handheld and desktop devices,
addressing critical-to-life applications. The Company’s devices are
used at the point-of-need to interrogate unknown and invisible
materials and provide quick, actionable answers to directly address
some of the most critical problems in life sciences research,
bioprocessing, pharma / biopharma, forensics and adjacent markets.
The Company is headquartered in the heart of Boston, where it
designs and manufactures innovative products that bring together
the power of mass spectrometry, microfluidic separations, software
automation, and machine learning.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210507005098/en/
Emily Fang PAN Communications for 908 Devices
908devices@pancomm.com
Carrie Mendivil, IR@908devices.com
908 Devices (NASDAQ:MASS)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
908 Devices (NASDAQ:MASS)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024